<?xml version='1.0' encoding='utf-8'?>
<document id="32009006"><sentence text="Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations." /><sentence text="In vitro data for low-dose inhaled phosphoinositide 3-kinase delta inhibitor nemiralisib revealed that it was a substrate and a potent metabolism-dependent inhibitor of cytochrome P450 (P450) 3A4 and a P-glycoprotein (P-gp) substrate" /><sentence text=" An integrated in silico, in vitro, and clinical approach including a clinical drug interaction study as well as a bespoke physiologically based pharmacokinetic (PBPK) model was used to assess the drug-drug interaction (DDI) risk" /><sentence text=" Inhaled nemiralisib (100 Âµg, single dose) was coadministered with itraconazole, a potent P4503A4/P-gp inhibitor, following 200 mg daily administrations for 10 days in 20 male healthy subjects"><entity charOffset="9-20" id="DDI-PubMed.32009006.s4.e0" text="nemiralisib" /><entity charOffset="67-79" id="DDI-PubMed.32009006.s4.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.32009006.s4.e0" e2="DDI-PubMed.32009006.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32009006.s4.e0" e2="DDI-PubMed.32009006.s4.e1" /></sentence><sentence text=" Systemic exposure to nemiralisib (AUC0-inf) increased by 2" /><sentence text="01-fold versus nemiralisib alone" /><sentence text=" To extrapolate the clinical data to other P4503A4 inhibitors, an inhaled PBPK model was developed using Simcyp software" /><sentence text=" Retrospective simulation of the victim risk showed good agreement between simulated and observed data (AUC0-inf ratio 2" /><sentence text="3 vs" /><sentence text=" 2" /><sentence text="01, respectively)" /><sentence text=" Prospective DDI simulations predicted a weak but manageable drug interaction when nemiralisib was coadministered with other P4503A4 inhibitors, such as the macrolides clarithromycin and erythromycin (simulated AUC0-inf ratio of 1"><entity charOffset="168-182" id="DDI-PubMed.32009006.s12.e0" text="clarithromycin" /><entity charOffset="187-199" id="DDI-PubMed.32009006.s12.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.32009006.s12.e0" e2="DDI-PubMed.32009006.s12.e0" /><pair ddi="false" e1="DDI-PubMed.32009006.s12.e0" e2="DDI-PubMed.32009006.s12.e1" /></sentence><sentence text="7), both common comedications in the intended patient populations" /><sentence text=" PBPK and static mechanistic models were also used to predict a negligible perpetrator DDI effect for nemiralisib on other P4503A4 substrates, including midazolam (a sensitive probe substrate of P4503A4) and theophylline (a narrow therapeutic index drug and another common comedication)"><entity charOffset="153-162" id="DDI-PubMed.32009006.s14.e0" text="midazolam" /><entity charOffset="208-220" id="DDI-PubMed.32009006.s14.e1" text="theophylline" /><pair ddi="false" e1="DDI-PubMed.32009006.s14.e0" e2="DDI-PubMed.32009006.s14.e0" /><pair ddi="false" e1="DDI-PubMed.32009006.s14.e0" e2="DDI-PubMed.32009006.s14.e1" /></sentence><sentence text=" In summary, an integrated in silico, in vitro, and clinical approach including an inhalation PBPK model has successfully discharged any potential patient DDI risks in future nemiralisib clinical trials" /><sentence text=" SIGNIFICANCE STATEMENT: This paper describes the integration of in silico, in vitro, and clinical data to successfully discharge potential drug-drug interaction risks for a low-dose inhaled drug"><entity charOffset="68-74" id="DDI-PubMed.32009006.s16.e0" text="silico" /></sentence><sentence text=" This work featured assessment of victim and perpetrator risks of drug transporters and cytochrome P450 enzymes, utilizing empirical and mechanistic approaches combined with clinical data (drug interaction and human absorption, metabolism, and pharmacokinetics) and physiologically based pharmacokinetic modeling approaches to facilitate bespoke risk assessment in target patient populations" /><sentence text="" /></document>